Nageshwar R. Budha, Ph.D.
Affiliations: | 2009 | Pharmaceutical Sciences | University of Tennessee Health Science Center, Memphis, TN, United States |
Area:
Pharmacology, Pharmaceutical ChemistryGoogle:
"Nageshwar Budha"Mean distance: (not calculated yet)
Parents
Sign in to add mentorBernd Meibohm | grad student | 2009 | UTHSC | |
(A pharmacokinetics and pharmacodynamics (PK/PD) guided approach to lead optimization of nitrofuranylamide anti-tuberculosis agents.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Saura C, Roda D, Roselló S, et al. (2016) A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors. Cancer Discovery |
Budha NR, Ji T, Musib L, et al. (2016) Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. Clinical Pharmacokinetics |
Tolcher A, Bendell JC, Papadopoulos KP, et al. (2016) A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Bonate PL, Ahamadi M, Budha N, et al. (2016) Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. Journal of Pharmacokinetics and Pharmacodynamics |
Chen Y, Ma F, Lu T, et al. (2015) Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction. Clinical Pharmacokinetics |
Han K, Jin JY, Marchand M, et al. (2015) Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology |
Budha NR, Leabman M, Jin JY, et al. (2015) Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9. The Aaps Journal. 17: 881-90 |
Peng K, Xu K, Liu L, et al. (2014) Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study. Mabs. 6: 1500-8 |
Yago MR, Frymoyer A, Benet LZ, et al. (2014) The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. The Aaps Journal. 16: 1358-65 |
Smelick GS, Heffron TP, Chu L, et al. (2013) Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Molecular Pharmaceutics. 10: 4055-62 |